{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:41:44Z","timestamp":1790066504482,"version":"4.0.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FIS","award":["CP14\/00133"],"award-info":[{"award-number":["CP14\/00133"]}]},{"name":"FIS","award":["PI16\/02057"],"award-info":[{"award-number":["PI16\/02057"]}]},{"name":"FIS","award":["PI18\/01366"],"award-info":[{"award-number":["PI18\/01366"]}]},{"name":"FIS","award":["PI19\/00588"],"award-info":[{"award-number":["PI19\/00588"]}]},{"name":"FIS","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}]},{"name":"FIS","award":["DTS18\/00032"],"award-info":[{"award-number":["DTS18\/00032"]}]},{"name":"ERA-PerMed-JTC2018"},{"name":"KIDNEY ATTACK","award":["AC18\/00064"],"award-info":[{"award-number":["AC18\/00064"]}]},{"name":"PERSTIGAN","award":["AC18\/00071"],"award-info":[{"award-number":["AC18\/00071"]}]},{"name":"ISCIII-RETIC REDinREN","award":["RD016\/0009"],"award-info":[{"award-number":["RD016\/0009"]}]},{"name":"Fondos FEDER, FRIAT, Sociedad Espa\u00f1ola de Nefrolog\u00eda, Comunidad de Madrid","award":["B2017\/BMD-3686"],"award-info":[{"award-number":["B2017\/BMD-3686"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis shed light on the complex world of glomerulonephritis therapy. However, they may no longer apply to idiopathic membranous nephropathy, as recently concluded by the KDIGO 2019 Working Group. This is due to the discovery of autoantibodies such as anti-phospholipase A2 receptor (anti-PLA2R) that allow disease monitoring as well as to results from recent clinical trials, comparative cohort studies and meta-analyses. Perhaps the most disruptive of them is the Membranous Nephropathy Trial of Rituximab (MENTOR) trial comparing rituximab with cyclosporine A, which supports the superiority of rituximab in efficacy and safety. Furthermore, rituximab results compared favourably with the short-term results of classical clinical trials that supported the KDIGO 2012 recommendation of immunosuppressive cyclophosphamide-based regimens as first choice for active treatment of idiopathic membranous nephropathy. Thus, the KDIGO recommendations for cyclophosphamide-based regimens or calcineurin inhibitors as the first line of active treatment regimens for idiopathic membranous nephropathy with nephrotic syndrome may no longer apply. By contrast, rituximab-based regimens or other B-cell-targeted therapies appear to represent the present and future of membranous nephropathy therapy.<\/jats:p>","DOI":"10.1093\/ckj\/sfz127","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T19:34:36Z","timestamp":1567020876000},"page":"629-638","source":"Crossref","is-referenced-by-count":38,"title":["Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal"],"prefix":"10.1093","volume":"12","author":[{"given":"Jorge Enrique","family":"Rojas-Rivera","sequence":"first","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain"},{"name":"Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Carriazo","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain"},{"name":"Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, Universidad Autonoma de Madrid, Madrid, Spain"},{"name":"Fundacion Renal I\u00f1igo Alvarez de Toledo-IRSIN, Madrid, Spain"},{"name":"REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2019093012020635000_sfz127-B1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"2019093012020635000_sfz127-B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2019093012020635000_sfz127-B4","first-page":"139","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2019093012020635000_sfz127-B5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"2019093012020635000_sfz127-B6","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B9","doi-asserted-by":"crossref","first-page":"e0184398","DOI":"10.1371\/journal.pone.0184398","article-title":"Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis","volume":"12","author":"Ren","year":"2017","journal-title":"PLoS One"},{"key":"2019093012020635000_sfz127-B10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int"},{"key":"2019093012020635000_sfz127-B11","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.1002942","article-title":"Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells","volume":"186","author":"Jang","year":"2011","journal-title":"J Immunol"},{"key":"2019093012020635000_sfz127-B12","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13 (Suppl 2)","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"2019093012020635000_sfz127-B13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"2019093012020635000_sfz127-B14","first-page":"1","article-title":"The role of \u03b2-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues","volume":"3","author":"Reddy","year":"2016","journal-title":"Am J Cancer Ther Pharmacol"},{"key":"2019093012020635000_sfz127-B15","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"2019093012020635000_sfz127-B16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2019093012020635000_sfz127-B17","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcibr0806881","article-title":"Proteinuria and immunity \u2013 an overstated relationship?","volume":"359","author":"Mathieson","year":"2008","journal-title":"N Engl J Med"},{"key":"2019093012020635000_sfz127-B18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2019093012020635000_sfz127-B19","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.142.10.3406","article-title":"Course of transplanted Heymann nephritis kidney in normal host. Implications for mechanism of proteinuria in membranous glomerulonephropathy","volume":"142","author":"Makker","year":"1989","journal-title":"J Immunol"},{"key":"2019093012020635000_sfz127-B20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B21","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/gfy049","article-title":"Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a health economic model","volume":"33","author":"Hamilton","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2019093012020635000_sfz127-B22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpneph1007","article-title":"Rituximab for membranous nephropathy and immune disease: less might be enough","volume":"5","author":"Ruggenenti","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"2019093012020635000_sfz127-B23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2019093012020635000_sfz127-B25","author":"Scolari"},{"key":"2019093012020635000_sfz127-B26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/12\/5\/629\/30088250\/sfz127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T15:46:21Z","timestamp":1695138381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/12\/5\/629\/5579346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz127","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,9,30]]}}}